Last reviewed · How we verify

Topiramate; Carbamazepine; Valproate

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Phase 3 active Small molecule

Topiramate; Carbamazepine; Valproate is a Anticonvulsants Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 3 development for Partial onset seizures, Generalized seizures, Migraine prophylaxis.

Topiramate is an anticonvulsant that acts as a voltage-dependent sodium channel blocker, whereas Carbamazepine is a tricyclic compound that stabilizes inactivated sodium channels, and Valproate is a fatty acid with anticonvulsant properties.

Topiramate is an anticonvulsant that acts as a voltage-dependent sodium channel blocker, whereas Carbamazepine is a tricyclic compound that stabilizes inactivated sodium channels, and Valproate is a fatty acid with anticonvulsant properties. Used for Partial onset seizures, Generalized seizures, Migraine prophylaxis.

At a glance

Generic nameTopiramate; Carbamazepine; Valproate
SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug classAnticonvulsants
TargetVoltage-dependent sodium channels
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Topiramate's mechanism of action is thought to involve the blockade of voltage-dependent sodium channels, which reduces the frequency of action potentials in neurons. Carbamazepine, on the other hand, stabilizes inactivated sodium channels, which prevents the excessive neuronal firing that can lead to seizures. Valproate's exact mechanism is not fully understood, but it is thought to involve the modulation of GABA receptors and the inhibition of voltage-dependent sodium channels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topiramate; Carbamazepine; Valproate

What is Topiramate; Carbamazepine; Valproate?

Topiramate; Carbamazepine; Valproate is a Anticonvulsants drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., indicated for Partial onset seizures, Generalized seizures, Migraine prophylaxis.

How does Topiramate; Carbamazepine; Valproate work?

Topiramate is an anticonvulsant that acts as a voltage-dependent sodium channel blocker, whereas Carbamazepine is a tricyclic compound that stabilizes inactivated sodium channels, and Valproate is a fatty acid with anticonvulsant properties.

What is Topiramate; Carbamazepine; Valproate used for?

Topiramate; Carbamazepine; Valproate is indicated for Partial onset seizures, Generalized seizures, Migraine prophylaxis.

Who makes Topiramate; Carbamazepine; Valproate?

Topiramate; Carbamazepine; Valproate is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).

What drug class is Topiramate; Carbamazepine; Valproate in?

Topiramate; Carbamazepine; Valproate belongs to the Anticonvulsants class. See all Anticonvulsants drugs at /class/anticonvulsants.

What development phase is Topiramate; Carbamazepine; Valproate in?

Topiramate; Carbamazepine; Valproate is in Phase 3.

What are the side effects of Topiramate; Carbamazepine; Valproate?

Common side effects of Topiramate; Carbamazepine; Valproate include Dizziness, Headache, Fatigue, Nausea, Drowsiness.

What does Topiramate; Carbamazepine; Valproate target?

Topiramate; Carbamazepine; Valproate targets Voltage-dependent sodium channels and is a Anticonvulsants.

Related